ANTI-TIGIT/ANTI-PVRIG BISPECIFIC ANTIBODY, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention belongs to the field of biological medicines, and relates to an anti-TIGIT/anti-PVRIG bispecific antibody, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to a bispecific antibody, comprising: a first protein functional region targeting PVRIG and a second protein functional region targeting a target (e.g., TIGIT) different from PVRIG, wherein the first protein functional region is an anti-PVRIG immunoglobulin or an antigen-binding fragment thereof; a heavy chain variable region of the anti-PVRIG immunoglobulin comprises HCDR1 having an amino acid sequence as set forth in SEQ ID NO: 25, HCDR2 having an amino acid sequence as set forth in SEQ ID NO: 26, and HCDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region of the anti-PVRIG immunoglobulin comprises LCDR1 having an amino acid sequence as set forth in SEQ ID NO: 22, LCDR2 having an amino acid sequence as set forth in SEQ ID NO: 23, and LCDR3 having an amino acid sequence as set forth in SEQ ID NO: 24. The bispecific antibody of the present invention has a good anti-tumor effect.